Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection

Next Previous
Trial Profile

A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP PA02 (Primary) ; Antibacterials
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections; Respiratory tract infections
  • Focus Adverse reactions; First in man
  • Acronyms SWARM-P.a.
  • Sponsors Armata Pharmaceuticals

Most Recent Events

  • 26 Aug 2024 According to an Armata Pharmaceuticals media release, Mina Pastagia, M.D., MS, Chief Medical Officer, will deliver a poster presentation at the 2024 Military Health System Research Symposium (MHSRS), held August 26-29 in Kissimmee, FL, providing an overview of two phage development programs AP-PA02 and AP-SA02 which are being or have been evaluated in three distinct double-blind, placebo-controlled Phase 2 clinical trials.
  • 07 May 2024 According to an Armata Pharmaceuticals media release, the company expected to submit to a peer-reviewed journal in the second quarter of 2024.
  • 21 Mar 2024 According to an Armata Pharmaceuticals, Inc. media release, the company plans to submit a manuscript detailing results from this trial to a peer-reviewed journal in the first half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top